SS:ORX Orexo AB Sponsored ADRs

Orexo AB (publ), a specialty pharmaceutical company, develops products based on proprietary drug delivery technology. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar, for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX338 sublingual tablet formulation of ketorolac for acute treatment of moderate to severe pain; and OX382, an oral formulation of buprenorphine and naloxone for treatment of opioid dependence. It is also developing OX-MPI program that has lead candidate drug BI1029539, an anti-inflammatory compound targeting microsomal prostaglandin E synthase. Orexo AB (publ) was founded in 1995 and is headquartered in Uppsala, Sweden.This company has ADRs that trade in the U.S. as the symbol ORXOY.

15.90 SEK
As of 03/08/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Unknown
Industry:  Drug Manufacturers-Specialty &
Index country:  Sweden
Country of incorporation:  Sweden
IPO date:  01/01/1900
Stock exchange:    Nasdaq Omx Nordic
Exchange country:   Sweden
Market cap:   627,514,048 SEK
Current dividend yield:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy